Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regulus Therapeutics, a joint venture between Alnylam Pharmaceutical and Isis Pharmaceuticals, formed to discover, develop, and commercialize microRNA-based therapeutics, has appointed Stelios Papadopoulos to its board of directors.
Subscribe to our email newsletter
Mr Papadopoulos will complement Regulus Therapeutics’s board of directors, which is comprised of industry leaders in drug discovery and development. Mr Papadopoulos retired as vice chairman of Cowen and Company in 2006.
Mr Papadopoulos holds a PhD in biophysics and an MBA in finance, both from New York University.
Kleanthis Xanthopoulos, president and CEO of Regulus, said: “We look forward to Dr Papadopoulos’s invaluable contributions as we continue to expand our therapeutic pipeline and bring lead microRNA therapeutic compounds closer to the clinic.”